Gadolinium‐modulated 19F signals from perfluorocarbon nanoparticles as a new strategy for molecular imaging
暂无分享,去创建一个
S. Caruthers | P. Winter | A. Neubauer | J. D. Robertson | S. Wickline | G. Lanza | Junjie Chen | J. Myerson | F. Hockett | P. Gaffney
[1] P. Stratta,et al. Gadolinium-enhanced magnetic resonance imaging, renal failure and nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy. , 2008, Current medicinal chemistry.
[2] Rika Takikawa,et al. [In-vivo visualization of gene expression using magnetic resonance imaging]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.
[3] T. Meade,et al. The synthesis and in vitro testing of a zinc-activated MRI contrast agent , 2007, Proceedings of the National Academy of Sciences.
[4] A. Kenwright,et al. Responsive fluorinated lanthanide probes for 19F magnetic resonance spectroscopy. , 2007, Chemical communications.
[5] S. Caruthers,et al. 19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[6] Garry E. Kiefer,et al. Imaging of Vx‐2 rabbit tumors with ανβ3‐integrin‐targeted 111In nanoparticles , 2007 .
[7] S. Caruthers,et al. Imaging of Vx-2 rabbit tumors with alpha(nu)beta3-integrin-targeted 111In nanoparticles. , 2007, International journal of cancer.
[8] Shelton D Caruthers,et al. Fluorine cardiovascular magnetic resonance angiography in vivo at 1.5 T with perfluorocarbon nanoparticle contrast agents. , 2007, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.
[9] Ralph Weissleder,et al. Imaging of myeloperoxidase in mice by using novel amplifiable paramagnetic substrates. , 2006, Radiology.
[10] Shelton D Caruthers,et al. In Vitro Demonstration Using 19F Magnetic Resonance to Augment Molecular Imaging With Paramagnetic Perfluorocarbon Nanoparticles at 1.5 Tesla , 2006, Investigative radiology.
[11] Eric T Ahrens,et al. In vivo imaging platform for tracking immunotherapeutic cells , 2005, Nature Biotechnology.
[12] P. Winter,et al. Improved Paramagnetic Chelate for Molecular Imaging with MRI , 2005 .
[13] J. McNab,et al. Tissue oxygen tension measurements in the Shionogi model of prostate cancer using 19F MRS and MRI , 2004, Magnetic Resonance Materials in Physics, Biology and Medicine.
[14] Patrick J. Gaffney,et al. Quantitative “magnetic resonance immunohistochemistry” with ligand‐targeted 19F nanoparticles , 2004 .
[15] Samuel A Wickline,et al. Quantitative "magnetic resonance immunohistochemistry" with ligand-targeted (19)F nanoparticles. , 2004, Magnetic resonance in medicine.
[16] Samuel A. Wickline,et al. Molecular Imaging of Angiogenesis in Early-Stage Atherosclerosis With &agr;v&bgr;3-Integrin–Targeted Nanoparticles , 2003 .
[17] K. Scheffler,et al. Principles and applications of balanced SSFP techniques , 2003, European Radiology.
[18] Sheng-Kwei Song,et al. Improved molecular imaging contrast agent for detection of human thrombus , 2003, Magnetic resonance in medicine.
[19] Shelton D Caruthers,et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. , 2003, Circulation.
[20] Kerry K. Karukstis,et al. Targeted Antiproliferative Drug Delivery to Vascular Smooth Muscle Cells With a Magnetic Resonance Imaging Nanoparticle Contrast Agent: Implications for Rational Therapy of Restenosis , 2002, Circulation.
[21] Xiaobing Fan,et al. Effect of carbogen on tumor oxygenation: combined fluorine-19 and proton MRI measurements. , 2002, International journal of radiation oncology, biology, physics.
[22] D. Cafiso,et al. Perfluorooctyl bromide has limited membrane solubility and is located at the bilayer center. Locating small molecules in lipid bilayers through paramagnetic enhancements of NMR relaxation. , 2002, Journal of medicinal chemistry.
[23] P. Winter,et al. Molecular imaging and targeted drug delivery with a novel, ligand-directed paramagnetic nanoparticle technology. , 2002, Academic radiology.
[24] S A Wickline,et al. Novel MRI Contrast Agent for Molecular Imaging of Fibrin: Implications for Detecting Vulnerable Plaques , 2001, Circulation.
[25] Peter Caravan,et al. Enzyme-Activated Gd3+ Magnetic Resonance Imaging Contrast Agents with a Prominent Receptor-Induced Magnetization Enhancement. , 2001, Angewandte Chemie.
[26] P. Antich,et al. Tumor oximetry: demonstration of an enhanced dynamic mapping procedure using fluorine-19 echo planar magnetic resonance imaging in the Dunning prostate R3327-AT1 rat tumor. , 2001, International journal of radiation oncology, biology, physics.
[27] S. Laurent,et al. Stability of MRI Paramagnetic Contrast Media: A Proton Relaxometric Protocol for Transmetallation Assessment , 2001, Investigative radiology.
[28] P. Antich,et al. Regional tumor oxygen dynamics: 19F PBSR EPI of hexafluorobenzene. , 1997, Magnetic resonance imaging.
[29] P. Gaffney,et al. Evaluation of the Fibrin Binding Profile of two Anti-fibrin Monoclonal Antibodies , 1996, Thrombosis and Haemostasis.
[30] P. Antich,et al. A Comparison of Three Commercial Perfluorocarbon Emulsions as High-Field 19F NMR Probes of Oxygen Tension and Temperature , 1995 .
[31] Stephen R. Thomas,et al. Evaluation of the influence of the aqueous phase bioconstituent environment on the F‐19 T1 of perfluorocarbon blood substitute emulsions , 1994, Journal of magnetic resonance imaging : JMRI.
[32] P. Antich,et al. Tumor oxygen tension: measurement using Oxygent as a 19F NMR probe at 4.7 T. , 1994, Artificial cells, blood substitutes, and immobilization biotechnology.
[33] S. Flaim. Pharmacokinetics and side effects of perfluorocarbon-based blood substitutes. , 1994, Artificial cells, blood substitutes, and immobilization biotechnology.
[34] R. Hurd,et al. 19F relaxation rate enhancement and frequency shift with Gd-DTPA. , 1989, Investigative radiology.